The registry for the PRIORITY study–Pregnancy CoRonavIrus Outcomes RegIsTrY–is enrolling pregnant women and those who have been pregnant or postpartum within the past six weeks who have a confirmed diagnosis of COVID-19 or are being evaluated for that possibility. UCLA Health's participation is aligned with the goals of UCLA Biodesign, a program that promotes health care innovation and partnerships that develop novel tools and technologies.
"We expect this registry to provide data that will be critical in helping to improve care for pregnant women during this global pandemic," said Yalda Afshar, MD, PhD, an obstetrician/gynecologist at UCLA Health and a UCLA Biodesign Fellow, who is co-principal investigator of the study.
Read the full UCLA press release.
UCLA CTSI is one of the proud partners of UCLA Biodesign.
CBS Newspath: Researchers seek COVID-19 effects on pregnancy